April exploring different routes of administration of its BiTE antibody
MT110 for the treatment of cancer.
* Insulet is an industry partner in a majority of the sites supporting
the Juvenile Diabetes Research Foundation's Artificial Pancreas
Project. As a result of the OmniPod System's role in the project, John
Garibotto, Insulet's Vice President of Research, Development &
Engineering, has been invited to participate in an upcoming
FDA-NIH-JDRF workshop on engineering considerations for building
a closed loop system.
* In the first quarter, Insulet announced two development agreements as
part of the Company's strategy to leverage the OmniPod System for
ongoing innovation. The agreement with DexCom to integrate its
continuous glucose monitoring technology into the wireless, handheld
OmniPod System Personal Diabetes Manager (PDM). The amended agreement
with Abbott Diabetes Care, Inc establishes Abbott's Freestyle blood
glucose monitor will be the exclusive strip meter available in
Financial Outlook for 2008
For the full year 2008, Insulet maintains its previously communicated guidance for full year 2008 revenue to be in the range of $40-45 million. The Company also maintains its expected 2008 net operating loss to be in the range of $55-60 million.
Insulet will host a conference call on Tuesday, May 13, 2008 at 5PM
Eastern time to discuss the Company's first quarter 2008 results and
present information concerning its business, strategies and outlook. To
listen to the conference call, please dial 866-277-1182 for domestic
callers and 617-597-5359 for international callers. The passcode is
40048264. A replay of the conference call will be available two hours after
the start of the call through June 12, 2008 by dialing 888-286-8010
|SOURCE Insulet Corporation|
Copyright©2008 PR Newswire.
All rights reserved